Queen Mary University of London launches new spinout Procyon Diagnostics to provide early cancer tests

▤ Summary

Queen Mary University of London has launched Procyon Diagnostics as a spinout focused on early cancer detection tests. The company closed an oversubscribed pre-seed round led by the university, with Source Bioscience and angel investors also participating. Procyon will use the money to support the UK launch, regulatory work, and international expansion of PancRISK, its pancreatic cancer test planned for early 2026. The product combines biomarker analysis and machine learning, and the company has already lined up a strategic partnership for software, storage, and testing scale-up.

$ Funding

▦ Linked Companies